In conclusion, plasma AKR1B10 alone and in combination with C3, as a noninvasive biomarker, performed well in the identification of NASH and advanced fibrosis, and is helpful for the longitudinal monitoring of the progression of or improvement in NAFLD. The gene discussed is AKR1B10; the disease is metabolic dysfunction-associated steatotic liver disease.